ImClone Systems Inc.

The company will pay $75 million to shareholders. The company allegedly violated security laws by misleading investors about the approval status of its cancer drug, Erbitux. The test medication was rejected by the FDA in early 2002, sending shares plummeting. (Jan-24-05) [CIO TODAY]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no obligation, please click the link below to submit your complaint.